Hospitality majors, including Le Meridien and Pride Hotel, are opposing pay channels such as Star and Zee for raising rates for the second time in six months, pending an earlier court battle between the hotel trade body and private broadcasters.
Aurobindo pharma, cipla, orchid chemicals are the prominent takeover targets.
The oil marketing companies are driving credit growth. The banking sector -- which typically sees credit contraction in the initial months -- has managed to buck the trend and has added nearly Rs 16,000 crore (Rs 160 billion) of advances in the first seven weeks of the current financial year thanks to the demand from the two sectors.
Health experts point out that it will take decades for India to reach the level of health education and infrastructure in developed countries. Our per capita health expenditure is estimated at $23, which is only 6.1 per cent of the gross domestic production.
Brushing aside objections over brand dilution, the government has reportedly begun work on modifying the IIT Act, 1961, to ensure that the eight new engineering institutes it is setting up come under the premier Indian Institute of Technology umbrella.
"We are looking at targets with a bottom line of Rs 50-60 crore (Rs 500-600 million) to expand our CRAMS business in various markets," said Ashok Shinkar, director, Wanbury. The company plans to increase its turnover to over Rs 900 crore (Rs 9 billion) within the next three years.
According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.
Hindustan Petroleum Corporation's wind power foray is facing teething troubles. The state-run company plans to set up 100 mw capacity at an investment of Rs 500 crore. Its first project - a pilot of 25 mw coming up in Maharashtra's Dhule district - is being shifted to Jaisalmer in Rajasthan following protests by farmers.
Voveran, Novartis India's flagship pain killer medicine, has become the largest selling domestic drug with sales of more than Rs 11 crore (Rs 110 million) in March 2008, displacing Pfizer India's cough and cold syrup Corex, which had sales of Rs 10 crore (Rs 100 million). Cipla, on the other hand, maintained its leadership position as the largest domestic pharmaceutical company edging out Ranbaxy Laboratories with a market share of 5.24 per cent.
Even as a heated debate goes on in the corridors of power and academic circles on the impact of large retail chains on small shops, in one sector it is clear that the big players are close to biting dust. At least two large pharmacy chains are up for sale, industry sources said. Some others have shaken up their top management, while a few have cut back on their expansions. One is trying to rediscover its business model by looking at rural markets. And all are woefully short o
The 300 mw Group Captive Power Project (GCPP) being set up by Vidarbha Industries Power (VIPL), a special purpose vehicle (SPV) formed by Reliance Power, at Butibori near Nagpur in Maharashtra, will soon enter the construction phase. Sources said the required land has been acquired and the Maharashtra Pollution Control Board (MPCB) has given the green signal for setting up the project. Reliance Power will soon award the EPC contract for the Rs 1500 crore project.
Ranbaxy Laboratories on Tuesday announced a business alliance with Orchid Chemicals and Pharmaceuticals across multiple geographies and therapies, for finished dosage formulations and bulk drugs. The new alliance will explore new products and markets without disturbing the existing alliances. The deal is independent of any commitment related to management control and is a pure arm's length, independent strategic biz alliance. Ranbaxy will benefit from Orchid's future products
In a move to catapult ayurveda to the main stream of healthcare in the country, the Tata Group is setting up the Indian Institute of Ayurveda Integrated Medicine in Bangalore. The institute will function in association with the Department of Science and Technology, and the Foundation for Revitalisation of Local Health Traditions, a Bangalore-based NGO that supports traditional healing methods.
The premier Indian Institutes of Management will have to draw on all their management skills to solve the current financial imbroglio they are in. On the one hand, the fee hike by IIM Ahmedabad and IIM Bangalore has caused heartburn not only among students and the Union Human Resource Development Ministry but also among the other IIMs who say they were not consulted despite an existing agreement to do so. IIM-A and IIM-B have said that a fee hike is a prerogative of their own
Anil Ambani-promoted Reliance Power (R-Power) has roped in international consultancy firm Ernst & Young (E&Y) to upgrade its Sasan ultra-mega power project (UMPP) in Madhya Pradesh to conform to the norms for receiving carbon credits.
Dr Reddy's Laboratories & Strides Arcolabs are at a risk of raiders as their promoter holdings are less than 26%. Promoters of Dr Reddy's have 25.15% stake as on Dec 31, 2007 and the share value of the company has dipped 19.9 per cent since January 1 this year. The Bangalore-based Strides Arcolab had only 18.82% promoter-holding as on Dec 31, 2007. The stock price of the company has gone down 34% in the same period. The promoters are taking steps to correct the situation.
Germany-based Humana Milchunion eG, one of the largest baby food products and therapeutic multivitamins manufacturers, will soon foray into India and neighbouring markets in a big way.
While the April to September period (H1) saw as many as eight major deals worth over Rs 5,000 crore (Rs 50 billion), the second half of the year saw a sharp drop in the value of such deals to about Rs 1,500 crore (Rs 15 billion). Though the number of deals in H1 and H2 is almost the same, the sharp decline in value in the second half indicates a clear change in outlook and strategy of companies, say industry experts.
They are of the view that calling the new institutes "IITs" would dilute the brand image of the existing premier institutes, which figure among the world's 100 best technology universities and are compared with the likes of MIT, California University and Berkeley. The seven IITs are located in Kharagpur, Mumbai, Chennai, Kanpur, Delhi, Guwahati and Roorkee.
The government appears to have hit upon a novel faculty-sharing solution to tackle the shortage of quality faculty at the premier Indian Institutes of Technology. The shortage will accentuate now that eight new IITs have been announced.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances